SYDNEY, Australia – OMG Pharma Australia (OMG), the scientific arm of the Oz Medicann Group and an architect in the Australian biotech scene specialising in cannabinoid medicine, is excited to announce a landmark partnership with global industry leader dsm- firmenich.
This strategic collaboration aims to transform the treatment landscape for insomnia with an innovative, pharmaceutical-grade CBD drug, in line with OMG’s extensive clinical research endeavours.
This collaboration seeks to introduce a pioneering CBD-based drug, featuring dsm- firmenich's highest quality GMP-certified CBD active pharmaceutical ingredient (API) to OMG’s phase 3 double blind placebo clinical trial for sleep insomnia. dsm-firmenich's CBD is uniquely formulated in a way that aims to enhance bioavailability of the final medicine and enable for the first time solid format medicines that meet the required medicine dose in a convenient way for the patient. This is a first-in-class ingredient enabling a first-in-class medicinal product. It signifies OMG’s commitment to pushing the boundaries of scientific discovery, drug development, and product innovation, aiming to set new treatment benchmarks for sleep disorders and propel the future of personalised medicine.
OMG is on a significant journey with several clinical trials in partnership with the NICM Health Research Institute at Western Sydney University and the Medical Research Institute of New Zealand in Wellington. Focused on sleep, anxiety, and pain, these trials epitomise OMG’s commitment to placing patients at the core of their R&D efforts.
Under the expert guidance of Emeritus Professor Alan Bensoussan, the comprehensive research includes testing a schedule 3 over-the-counter sublingual CBD tablet for insomnia, a CBD salve for inflammatory conditions, and a sublingual CBD tablet for anxiety. This initiative reflects OMG’s goal to create research-based, scientifically driven solutions that meet the unmet medical needs of patients and enhance patient health outcomes.
The insomnia clinical trial is set to be a milestone, potentially introducing the world's first regulatory-approved over-the-counter CBD sleep tablet. This double-blind, randomised, placebo-controlled trial will evaluate the eYicacy of two CBD dosages against a placebo, marking a significant advancement for those suffering from sleep disturbances.
The collaboration between OMG and dsm-firmenich represents more than a partnership; it's a shared journey towards excellence in CBD therapy development. With a strong foundation in scientific integrity and innovation, this collaboration aims to redefine the standards in cannabinoid pharmaceutical applications, improving patient care globally.
"This collaboration with dsm-firmenich marks a significant milestone in OMG’s journey. We chose dsm-firmenich as our partner because of our shared vision for science-led, evidence- based solutions. dsm-firmenich is at the forefront of driving innovation in product development and scientific rigor. Together, we are not just developing treatments; we are setting new standards for the future of healthcare and patient well-being."
OMG Pharma Australia, the science division of the OZ Medicann Group, leads the charge in cannabinoid medicine, pioneering scientific research, drug development, and product innovation. Dedicated to revolutionising personalised medicine, OMG Pharma Australia is committed to providing groundbreaking treatments for a diverse range of conditions, prioritising patient-centered approaches.
https://www.omgpharma.com.au
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss- Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people.
www.dsm-firmenich.com
For further information, please contact: John Leith: johnl@ozmedicann.com or Rohit Bhuta: rohitb@ozmedicann.com
Copyright © OZ Medicann Group Pty Ltd. Australia - 2024. Privacy Policy
Copyright © OZ Medicann Group Pty Ltd. Australia - 2024. Privacy Policy